Abstract Details

Title Incidence and trends of Frontotemporal Disorders in Olmsted County: a population based study (1995-2010).

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P2 - Poster Session 2 (5:30 PM-6:30 PM)

Poster/Presentation
Number 9-001

Objective Explore the incidence of Frontotemporal dementia Disorders (FTDs) in a population-based cohort.

Background

FTDs are heterogeneous phenotypical syndromes, characterized by behavioral and language disorders usually associated with frontal and/or temporal lobes degeneration.

Design/Methods Using the records-linkage system of the Rochester Epidemiology Project, we identified all patients with a screening diagnostic code for dementia in Olmsted County, MN from 1995 to 2010. We used natural language processing software to confirm the presence of FTDs diagnoses. A behavioral neurologist verified the clinical diagnosis and determined clinical phenotypes.

Results We identified 35 FTDs cases: 22 (62.9%) were male. Median age at diagnosis was 70 years (range: 48-94). Median follow-up time was 3 years (range: 1 month-12 years). 17/35 (48.6%) had behavioral variant FTD; 1 had a mixed clinical diagnosis (behavioral variant + semantic variant FTD); 1 had fluent primary progressive aphasia (PPA); 1 non-fluent PPA; 1 PPA NOS; 1 had FTD with motor neuron disease; and 13/35 (37.1%) were unspecified. 10/35 (28.6%) reported depression within 5 years preceding the clinical diagnosis. 13/35 (37.1%) patients had at least one MRI before their diagnosis (range: 3 days- 6 years); all presented with cortical atrophy consistent with the clinical diagnosis. 6/35 (17.1%) patients underwent PET or SPECT examination before the clinical diagnosis (range: 1 month-19 months), all showing hypometabolism of the frontal, temporal and/or parietal lobes. At autopsy, clinical diagnosis was confirmed in 6/11 (54.5%) cases. Overall FTDs incidence was 4.3/100,000 per year (95% CI 2.9, 5.7, P<0.001). Incidence was higher in men (6.3/100,000, 95% CI 3.6, 9.0, P<0.001) than women (2.9/100,000; 95% CI 1.3, 4.5, P<0.001). Incidence trended upwards over time (B= 0.83, 95% CI 0.54, 1.11, P<0.001).

Conclusions

We observed an increased incidence of FTDs over time. This may reflect a better recognition by clinicians, and improvement of clinical criteria and diagnostic tools.

Authors/Disclosures
Pierpaolo Turcano, MD (Rush University Medical Center) PRESENTER	Dr. Turcano has nothing to disclose.
Cole D. Stang	Mr. Stang has nothing to disclose.
Michelle M. Mielke, PhD (Wake Forest University School of Medicine)	Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LabCorp. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Siemens Healthineers. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sunbird Bio. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk.
	No disclosure on file
Keith A. Josephs, Jr., MD, FAAN (Mayo Clinic)	Dr. Josephs has nothing to disclose.
J. E. Ahlskog, MD, PhD (Mayo Clinic)	Dr. Ahlskog has received publishing royalties from a publication relating to health care.
Bradley F. Boeve, MD, FAAN (Mayo Clinic)	Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.
David S. Knopman, MD, FAAN (Mayo Clinic)	Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Ronald C. Petersen, MD, PhD, FAAN (Mayo Clinic)	Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.
Rodolfo Savica, MD, PhD, FAAN (Mayo Clinic)	The institution of Dr. Savica has received research support from ACADIA Pharmaceuticals, Inc.

��ɫ��

��ɫ��